Inventiva has been granted a patent for a novel compound defined by formula (I), with specific substituents R1, R2, R3, R4, and R5 as detailed in the accompanying description. The patent covers the unique structural composition of these compounds. GlobalData’s report on Inventiva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inventiva, Human telomerase RT biomarker was a key innovation area identified from patents. Inventiva's grant share as of June 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Compounds of formula (i) for pharmaceutical applications
The granted patent US11999758B2 encompasses a series of claims related to novel compounds, specifically those represented by a defined chemical formula (I) and its derivatives. The claims detail various structural modifications of the compounds, including specific substituents such as alkyl, aryl, and functional groups like hydroxy, alkoxy, and halogens. Notably, the patent outlines a range of compounds that can be utilized in pharmaceutical applications, particularly those that can be formulated as pharmaceutically acceptable salts. The claims also specify particular compounds of interest, including various boronic acids and their derivatives, which may have potential therapeutic applications.
In addition to the compounds, the patent describes methods for treating cancers characterized by the localization of the YAP protein in the nucleus of tumor cells. The specified cancers include lung, thyroid, ovarian, colorectal, prostate, pancreas, esophagus, liver, breast, skin cancers, and malignant mesothelioma. The patent further includes claims for pharmaceutical compositions that combine the identified compounds with acceptable excipients, emphasizing their potential utility in cancer treatment. Overall, the patent presents a comprehensive framework for the development of new therapeutic agents targeting specific cancer types through the modulation of YAP localization.
To know more about GlobalData’s detailed insights on Inventiva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
